Ribosomal dysfunction, as a critical determinant in AML pathogenesis, progression, and treatment resistance, has emerged as a therapeutic target, supported by mechanistic links to leukemogenesis involving aberrant ribosomal biosynthesis, translational regulation, and ribosomal protein (RP) mutations. This evidence concerns the gene BLOC1S3 and acute myeloid leukemia.